Eli Lilly said its experimental amylin receptor agonist eloralintide met predefined efficacy thresholds and will advance into Phase 3 testing after phase 2 results showing up to 20.1% weight loss at Week 48. The randomized study enrolled 263 adults with obesity or overweight and comorbidities and showed dose‑dependent responses with tolerability improving under slower titration. Lilly frames eloralintide’s selectivity for amylin receptors as a differentiator versus competitors like Novo’s cagrilintide and combo amylin/GLP‑1 agents, which have reported similar high‑double‑digit weight loss when combined with GLP‑1 therapies. The company noted main adverse events were gastrointestinal symptoms and fatigue, with lower incidence at conservative dose escalation. The data position Lilly as a serious contender in the amylin class and could reshape competitive dynamics in the obesity therapeutics market.